

CITATION REPORT

List of articles citing

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

DOI: 10.1001/jama.2014.5985

JAMA - Journal of the American Medical Association,
2015, 313, 1347-61.

Source: <https://exaly.com/paper-pdf/62230663/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
345	Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF- κ B Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. 2015 , 2, 1331-9		41
344	Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?. 2015 , 2, 85		21
343	"OMIC" tumor markers for breast cancer: A review. 2015 , 31, 1256-62		10
342	BRCA1 185delAG Mutation Enhances Interleukin-1 β Expression in Ovarian Surface Epithelial Cells. 2015 , 2015, 652017		6
341	Curating the way to better determinants of genetic risk. 2015 , 372, 2227-8		12
340	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. 2015 , 5, 1137-54		436
339	Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. 2015 , 3, 13		18
338	Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review. 2015 , 15, 1383-403		26
337	The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know. 2015 , 24, 705-32		3
336	Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. 2016 , 7, 80465-80481		39
335	"DNA Binding Region" of BRCA1 Affects Genetic Stability through modulating the Intra-S-Phase Checkpoint. 2016 , 12, 133-43		15
334	Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. 2016 , 10, 626		24
333	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. 2016 , 7, 37331-37346		59
332	Differences of Variable Number Tandem Repeats in XRCC5 Promoter Are Associated with Increased or Decreased Risk of Breast Cancer in BRCA Gene Mutation Carriers. 2016 , 6, 92		7
331	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. 2016 , 6, 119		12
330	Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. 2016 , 7, 85529-85541		30
329	Management of women with a hereditary predisposition for breast cancer. 2016 , 12, 2277-88		7

328	Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. <i>BMC Cancer</i> , 2016 , 16, 934	4.8	33
327	B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. 2016 , 36, 231-8		12
326	RANKL/RANK: from bone loss to the prevention of breast cancer. 2016 , 6,		37
325	Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. 2016 , 156, 441-445		18
324	Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study. 2016 , 32, 65-71		18
323	The BRCA1- Δ 1q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. 2016 , 76, 2778-90		136
322	Unsolved mystery: the role of BRCA1 in DNA end-joining. 2016 , 57 Suppl 1, i18-i24		26
321	Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific. 2016 , 18, 87		6
320	BRCA to the future: towards best testing practice in the era of personalised healthcare. 2016 , 24 Suppl 1, S1-2		11
319	Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. 2016 , 27, v103-v110		202
318	Hereditary breast and ovarian cancer: new genes in confined pathways. 2016 , 16, 599-612		210
317	Listing author contribution does not alter the author inflation in the publications in basic research in four major gastroenterology journals in 10 years. 2016 , 107, 1501-1507		3
316	Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. 2016 , 23, T69-84		46
315	Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. 2016 , 139, 1091-7		36
314	Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect. 2016 , 25, 5287-5299		2
313	Ovarian cancer. 2016 , 2, 16061		420
312	Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women. 2016 , 127, 848-858		23
311	Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. 2016 , 209, 417-422		26

310	Cancer du sein : risque génétique. 2016 , 26, 95-104	3
309	Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. 2016 , 23, R267-85	26
308	Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium. 2016 , 37, 12329-12337	10
307	BRCAness revisited. 2016 , 16, 110-20	678
306	A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 2016 , 25, 193-200	47
305	BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population. 2016 , 15, 507-12	8
304	The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. 2016 , 374, 454-68	179
303	Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations. 2016 , 43, 335-8	1
302	The promise and peril of genomic screening in the general population. 2016 , 18, 593-9	40
301	The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer. 2016 , 15, 111-21	18
300	Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients. 2017 , 16, 329-338	2
299	Genetics of gynaecological cancers. 2017 , 42, 114-124	11
298	Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function. 2017 , 18, 947-960	17
297	BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. 2017 , 140, 2051-2059	31
296	Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series. 2017 , 214-215, 1-8	3
295	Exploiting Homologous Recombination Deficiency in TNBC. 2017 , 9, 52-59	
294	Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 2017 , 24, 837-842	14
293	DNA Damage and Repair Biomarkers of Immunotherapy Response. 2017 , 7, 675-693	331

292	What about prophylactic surgery in BRCA1/BRCA2 mutation carriers? Observations from an Italian pilot study. 2017 , 23, 766-767	
291	A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability. 2017 , 169, 1105-1118.e15	93
290	Clinical outcomes of female breast cancer according to BRCA mutation status. 2017 , 49, 128-137	5
289	Precancer Atlas to Drive Precision Prevention Trials. 2017 , 77, 1510-1541	81
288	Ovarian Cancer Prevention in High-risk Women. 2017 , 60, 738-757	15
287	Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. 2017 , 147, 705-713	48
286	Congrès l'Association américaine de recherche contre le cancer l'ACR 2017. 2017 , 19, 209-230	
285	Randomized Controlled Trials in Hereditary Cancer Syndromes. 2017 , 26, 729-750	2
284	Genetic testing in women with breast cancer: implications for treatment. 2017 , 17, 991-1002	7
283	Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?. 2017 , 296, 1055-1062	32
282	Oleuropein represses the radiation resistance of ovarian cancer by inhibiting hypoxia and microRNA-299-targetted heparanase expression. 2017 , 8, 2857-2864	15
281	Screening for familial cancer risk: Focus on breast cancer. 2017 , 105, 69-77	18
280	Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms. 2017 , 24, 601-609	3
279	Breast Cancer Genetics. 2017 , 73-86	
278	Response to Dr. Sorscher. 2017 , 26, 1164	
277	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. 2017 , 161, 117-134	15
276	Dominant Traits and Diseases. 2017 , 1-7	
275	Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population. 2018 , 15, 3068-3074	4

274	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. 2017 , 10, 2539-2551		30
273	Monoallelic characteristic-bearing heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer. 2017 , 18, 85		3
272	DNA Repair Pathway Alterations in Bladder Cancer. <i>Cancers</i> , 2017 , 9,	6.6	26
271	Orthodox Jewish Thought Leaders' Insights Regarding BRCA Mutations: A Descriptive Study. 2017 , 13, e303-e309		4
270	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. 2017 , 35, 2240-2250		101
269	germline mutations dominate familial breast cancer patients in Henan China. 2017 , 9, 5295-5299		4
268	The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?. 2018 , 26, 848-857		4
267	Penetrance estimates for , (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. <i>Journal of Medical Genetics</i> , 2018 , 55, 442-448	5.8	1
266	A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. 2018 , 27, 1187-1199		23
265	Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers. 2018 , 18, 362-373.e1		3
264	Towards Prevention of Breast Cancer: What Are the Clinical Challenges?. 2018 , 11, 255-264		5
263	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. 2018 , 39, 593-620		138
262	BRCA2 Regulates Transcription Elongation by RNA Polymerase II to Prevent R-Loop Accumulation. 2018 , 22, 1031-1039		68
261	Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research. 2018 , 19, e102-e112		8
260	Multi-gene Panel Testing in Breast Cancer Management. 2018 , 173, 121-140		10
259	BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far. 2018 , 42, 189-207		13
258	Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families. 2018 , 7, 46-55		18
257	Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies. 2018 , 15, 641-663		5

256	mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. 2018 , 16, 3	12
255	Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. 2018 , 19, 341-353	21
254	The Cancer Worry Scale Revised for Breast Cancer Genetic Counseling. 2018 , 41, 311-319	7
253	BRCA1 gene: function and deficiency. 2018 , 23, 36-44	49
252	A risk score including body mass index, glycated haemoglobin and triglycerides predicts future glycaemic control in people with type 2 diabetes. 2018 , 20, 681-688	17
251	Population-Based Cohort Study Reveals Distinct Associations Between Female Lung Cancer and Breast Cancer in Taiwan. 2018 , 2, 1-14	5
250	Ovarian Cancer Genetics: Subtypes and Risk Factors. 2018 ,	8
249	Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition. 2018 , 14, 189-193	10
248	Admixture, Genetics and Complex Diseases in Latin Americans and US Hispanics. 2018 , 6, 208-223	7
247	Mass spectrometry-based proteomics techniques and their application in ovarian cancer research. 2018 , 11, 88	16
246	GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in and Pathogenic Variant Carriers. 2018 , 8, 490	10
245	Knockdown of BRCC3 exerts an anti-tumor effect on cervical cancer in vitro. 2018 , 18, 4886-4894	6
244	Risk and Prevention for Highly Penetrant Genes. 2018 , 10, 209-218	
243	Drilling for Insight: Forecasting Phenotype from Genotype. 2018 , 34, 821-822	3
242	Interplay Between Genetic and Epigenetic Changes in Breast Cancer Subtypes. 2018 , 1856, 19-34	10
241	Mixing Mutation Location With Carcinogen Exposure: A Recipe for Tissue Specificity in BRCA2-Associated Cancers?. 2018 , 110, 925-926	
240	Cancer genetics, precision prevention and a call to action. 2018 , 50, 1212-1218	57
239	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. 2018 , 150, 85-91	47

238 The Role of Genomics. **2018**, 55-71

237 BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study. **2018**, 13, e0201086 10

236 BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. **2018**, 151, 145-152 23

235 BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. **2018**, 12, 39 11

234 A subregion-based burden test for simultaneous identification of susceptibility loci and subregions within. **2018**, 42, 673-683 3

233 Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study. *BMC Cancer*, **2018**, 18, 800 4.8 5

232 BRCA1/2 testing: therapeutic implications for breast cancer management. **2018**, 119, 141-152 84

231 Precision Prevention and Early Detection of Cancer: Fundamental Principles. **2018**, 8, 803-811 40

230 The BRCA1 exon 13 duplication: clinical characteristics of 22 families in Northern Sweden. **2019**, 18, 37-42

229 dbCID: a manually curated resource for exploring the driver indels in human cancer. **2019**, 20, 1925-1933 8

228 Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. *BMC Cancer*, **2019**, 19, 787 4.8 3

227 Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model. **2019**, 18, 381-388 4

226 A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements. **2019**, 2019, 4382606 22

225 [Inherited predisposition to breast cancer (2) : risks and surveillance]. **2019**, 35, 332-345 0

224 How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?. **2019**, 81, 102668 30

223 Frequency of Pathogenic Germline Variants in , and in Sporadic Lobular Breast Cancer. **2019**, 28, 1162-1168 12

222 Enrichment of heterozygous germline loss-of-function variants in pediatric osteosarcoma. **2019**, 5, 12

221 The c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability. *Genes*, **2019**, 10, 4.2 8

220	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. 2020 , 80, 624-638		22
219	Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort. 2019 , 20, 150		4
218	Spectrum and prevalence of germline mutations in Pakistani breast cancer patients: results from a large comprehensive study. 2019 , 17, 27		11
217	Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients. 2019 , 14, e0222709		4
216	Identification of BRCA1/2 p.Ser1613Gly, p.Pro871Leu, p.Lys1183Arg, p.Glu1038Gly, p.Ser1140Gly, p.Ala2466Val, p.His2440Arg variants in women under 45 years old with breast nodules suspected of having breast cancer in Burkina Faso. 2019 , 10, 120-127		4
215	DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. 2019 , 80, 59-84		15
214	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. 2019 , 121, 180-192		13
213	Cancer Genetics: Risks and Mechanisms of Cancer in Women with Hereditary Predisposition to Epithelial Ovarian Cancer. 2019 , 29-43		
212	is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation. <i>Cancers</i> , 2019 , 11,	6.6	18
211	Prevention of Ovarian Cancer. 2019 , 257-272		
210	Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer. 2019 , 17, 3687-3700		5
209	Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas. 2019 , 20, 843-854		9
208	BRCA gene mutations: A population based review. 2019 , 15, 100380		
207	Influence of obesity on surgical complications of patients with ovarian tumors. 2019 , 17, 4590-4594		1
206	Disparities in Cancer Incidence among Chinese Population versus Migrants to Developed Regions: A Population-Based Comparative Study. 2019 , 28, 890-899		4
205	[Hereditary predisposition to breast cancer (1): genetics]. 2019 , 35, 138-151		1
204	Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. <i>Cancers</i> , 2019 , 11,	6.6	11
203	Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients. 2019 , 8, 1875-1881		10

202	Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). <i>Journal of Medical Genetics</i> , 2019 , 56, 370-379	5.8	21
201	Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. 2019 , 25, 2963-2968		20
200	Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing. 2019 , 84, 160-169		2
199	Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis. 2019 , 12, 110		13
198	Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain). <i>BMC Cancer</i> , 2019 , 19, 1145	4.8	8
197	Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches. 2019 , 25, 287-295		2
196	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. 2019 , 10, 5661		25
195	Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing. 2019 , 20, 633-641		
194	Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. 2019 , 21, 1076-1084		6
193	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. 2019 , 133, 58-73		20
192	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. 2019 , 111, 350-364		22
191	Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. 2019 , 125, 698-703		16
190	Genotype-Phenotype Associations of APC Mutations With Pouch Adenoma in Patients With Familial Adenomatous Polyposis. 2019 , 53, e54-e60		4
189	Discovery and Characterization of Cancer Genetic Susceptibility Alleles. 2020 , 323-336.e3		1
188	Melanoma predisposition-A limited role for germline BRCA1 and BRCA2 variants. 2020 , 33, 6-7		2
187	Metformin Abrogates Age-Associated Ovarian Fibrosis. 2020 , 26, 632-642		23
186	BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese. 2020 , 146, 1042-1051		19
185	Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations. 2020 , 156, 363-376		1

184	Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients. 2020 , 13, 212-220	6
183	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. 2020 , 156, 377-386	9
182	Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. 2020 , 31, 1545-1552	5
181	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. 2020 , 6, 54	58
180	Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays. 2020 , 22, 23	3
179	Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. 2020 , 26, 1520-1527	5
178	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. 2020 , 22, 1653-1666	34
177	Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers. 2020 , 6, 559-568	5
176	BRCA2 c.8827C>T pathogenic mutation in a consanguineous Chinese family with hereditary breast cancer. 2020 , 8, e1411	1
175	Mutations in and differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. 2021 , 1, 1188-1203	43
174	Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors. 2021 , 20, 189-194	
173	Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1 and BRCA2 mutation carriers. 2021 , 77, 110-126	9
172	Targeting progesterone signaling prevents metastatic ovarian cancer. 2020 , 117, 31993-32004	9
171	gene testing in women with high-grade serous ovarian carcinoma. 2021 , 41, 962-965	1
170	BRCA1/2 Variants and Metabolic Factors: Results From a Cohort of Italian Female Carriers. <i>Cancers</i> , 2020 , 12,	6.6 2
169	Identification of Novel and Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. <i>Frontiers in Genetics</i> , 2020 , 11, 552971	4.5 6
168	MiRNAs: A Powerful Tool in Deciphering Gynecological Malignancies. 2020 , 10, 591181	6
167	Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. 2020 , 10, 9477-9494	7

166	Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis. 2020 , 26, 962-970		0
165	Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. 2020 , 184, 229-235		6
164	Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. 2021 , 28, 1167-1180		29
163	Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. 2020 , 123, 1608-1615		1
162	Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition. <i>Scientific Reports</i> , 2020 , 10, 13987	4.9	3
161	BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. 2020 , 13, 50		20
160	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in Genes. <i>Cancers</i> , 2020 , 12,	6.6	14
159	Legacy Genetic Testing Results for Cancer Susceptibility: How Common are Conflicting Classifications in a Large Variant Dataset from Multiple Practices?. 2020 , 27, 2212-2220		0
158	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. 2020 , 18, 1315-1325		3
157	Practical implementation of frailty models in Mendelian risk prediction. 2020 , 44, 564-578		1
156	Prostate Cancer Risk by BRCA2 Genomic Regions. 2020 , 78, 494-497		2
155	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. 2020 , 6, 439-452		9
154	Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. <i>BMC Cancer</i> , 2020 , 20, 204	4.8	9
153	DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome. <i>Cancers</i> , 2020 , 12,	6.6	12
152	Precise and Programmable Detection of Mutations Using Ultraspecific Riboregulators. 2020 , 180, 1018-1032.e16		16
151	Group plus "mini" individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction. 2020 , 18, 3		2
150	The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer. 2020 , 180, 759-766		5
149	The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study. 2020 , 247, 26-31		4

148	Genetically Engineered Pigs to Study Cancer. 2020 , 21,	20
147	Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. <i>Scientific Reports</i> , 2020 , 10, 7073	4.9 24
146	Population Screening for Inherited Predisposition to Breast and Ovarian Cancer. 2020 , 21, 373-412	17
145	Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. 2020 , 8, 160	16
144	Molecular Trajectory of and Mutations. 2020 , 10, 361	24
143	A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. 2021 , 32, 103-112	38
142	RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target. 2021 , 41, 586-615	2
141	Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration. 2021 , 66, 379-387	1
140	Variation in cancer risk among families with genetic susceptibility. 2021 , 45, 209-221	0
139	Phenotype evaluation and clinical context: application of case-level data in genomic variant interpretation. 2021 , 251-274	
138	Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. 2021 , 27, 41-49	5
137	Association of Germline BRCA Pathogenic Variants with Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.	1
136	Further delineation of the NTHL1 associated syndrome: A report from the French Oncogenetic Consortium. 2021 , 99, 662-672	1
135	Inbred Strain Characteristics Impact the NKT Cell Repertoire. 2021 , 5, 147-156	
134	Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. 2021 , 7, 18	1
133	Recent Advances in Therapeutic Peptides for Breast Cancer Treatment. 2021 , 22, 74-88	6
132	Basic and Preclinical Research for Personalized Medicine. 2021 , 11,	2
131	Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers. <i>Cancers</i> , 2021 , 13,	6.6 0

130	Generation and characterization of induced pluripotent stem cells heterozygous for the Portuguese BRCA2 founder mutation. 2021 , 53, 102364		1
129	A Population-Based Analysis of / Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	1
128	Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. 2021 , 39, 2016-2024		10
127	Evaluation of two population screening programmes for founder mutations in the Australian Jewish community: a protocol paper. 2021 , 11, e041186		1
126	Precision medicine in pediatric solid cancers. 2021 ,		4
125	Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. 2021 , 112, 3338-3348		2
124	Prevalence and Spectrum of Germline and Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. 2021 , 11, 682445		6
123	No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in or Mutation Families. <i>Genes</i> , 2021 , 12,	4.2	
122	Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries. 2021 , 28, 1367-1382		
121	Differences in Ovarian and Other Cancers Risks by Population and Mutation Location. <i>Genes</i> , 2021 , 12,	4.2	1
120	The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. <i>Cancers</i> , 2021 , 13,	6.6	2
119	A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.		
118	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. 2021 ,		3
117	Risks and Function of Breast Cancer Susceptibility Alleles. <i>Cancers</i> , 2021 , 13,	6.6	1
116	Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study. 2021 ,		1
115	Guardians of the Genome: BRCA2 and Its Partners. <i>Genes</i> , 2021 , 12,	4.2	2
114	A framework for integrated clinical risk assessment using population sequencing data.		0
113	Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. 2021 , 42, 1488-1502		0

112	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for and Mutation Carriers: Assessing the Evidence. 2021 , 14, 983-994	2
111	Identification of Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology. <i>Frontiers in Genetics</i> , 2021 , 12, 674990	4.5
110	High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer. 2021 , 1	0
109	Identification of Eleven Novel Mutations in Tunisia: Impact on the Clinical Management of Related Cancers. 2021 , 11, 674965	1
108	Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer. 2021 , 406, 112742	2
107	The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome. <i>Genes</i> , 2021 , 12,	4.2
106	The Paradigms in Breast Cancer Prevention. 2016 , 1-21	1
105	Emerging roles of lamins and DNA damage repair mechanisms in ovarian cancer. 2020 , 48, 2317-2333	5
104	Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study. 2020 , 111, 3350-3358	3
103	pathogenic variants in triple-negative luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. 2020 , 12, 1758835920975326	19
102	[Differential expression of miR-126-5p in lung adenocarcinoma and the possible mechanism]. 2019 , 39, 1186-1190	3
101	High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer. 2015 , 10, e0140572	42
100	Haplotypic characterization of BRCA1 c.5266dupC, the prevailing mutation in Brazilian hereditary breast/ovarian cancer. 2020 , 43, e20190072	2
99	Ovarian hormones through Wnt signalling regulate the growth of human and mouse ovarian cancer initiating lesions. 2016 , 7, 64836-64853	14
98	FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. 2016 , 7, 75729-75738	6
97	BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. 2017 , 8, 22640-22648	8
96	Identifying prognostic signature in ovarian cancer using DirGenerank. 2017 , 8, 46398-46413	9
95	Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation L63X. 2019 , 10, 3276-3284	9

94	Efficacy of platinum in advanced triple-negative breast cancer with germline mutation determined by next generation sequencing. 2020 , 32, 149-162		7
93	Spectrum of Germline and Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome. <i>Cancers</i> , 2020 , 12,	6.6	7
92	Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review. 2019 , 51, 941-950		7
91	Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant. 2020 , 52, 680-688		5
90	Identification of novel large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data. 2019 , 7, e7972		1
89	Hereditary Cancers and Genetics. 2021 , 65-98		
88	Screening Women With Known or Suspected Cancer Gene Mutations. 2016 , 265-298		
87	Genetics of Ovarian Carcinomas. 2017 , 13-31		
86	Prophylactic Oophorectomy for Patients with Germline BRCA Mutations. 2017 , 65-87		
85	Risk-Reducing Surgery for BRCA1/2 Genetic Mutation Carriers. 2017 , 47-63		
84	Hereditary Ovarian Cancer. 2017 , 15-35		
83	Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. 2018 , 10, e2685		2
82	Mutational analysis of BRCA1 and BRCA2 in northwest Chinese breast cancer patients.. 2019 , 8, 1845-1852		1
81	The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study. 2020 , 54, 180-186		2
80	Homologous recombination proficiency in ovarian and breast cancer patients. <i>BMC Cancer</i> , 2021 , 21, 1154	4.8	2
79	Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future. 2020 , 41, 9-14		
78	Clinicopathological analysis of early-stage breast cancer patients that meet indications for genetic testing. 2020 , 32, 163-174		
77	Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique. 2020 , 21, 431-438		3

76	Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors. 2021 , 9, 764275		0
75	The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience. <i>Cancers</i> , 2021 , 13,	6.6	1
74	Effects of BRCA gene mutation on female reproductive potential: A systematic review. 2020 , 137, 11-17		1
73	Assessing the variations in breast/ovarian cancer risk for Chinese BRCA1/2 carriers.		
72	A meta-analysis of clinical cases of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.		
71	Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 619027	5.6	2
70	Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer. 2021 , 260-261, 14-17		0
69	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. 2021 ,		2
68	Hereditary Ovarian Cancer. 2021 , 93-106		
67	Risk-Based Breast Cancer Screening. 2021 , 107-128		
66	Genetic Testing. 2021 , 31-46		
65	History, Advancements, and Future Strategies. 2021 , 1-14		
64	Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers.. <i>Cancers</i> , 2022 , 14,	6.6	0
63	Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.. 2022 ,		0
62	The Risks of Breast and Ovarian Cancer Associated with the Ashkenazi Jewish Founder Allele BRCA2 6174delT.. 2021 ,		
61	Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome.. <i>Genes</i> , 2022 , 13,	4.2	
60	Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.. 2021 ,		1
59	PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.. 2022 , 104, 102359		0

58	The BRCA Gene in Epithelial Ovarian Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	1
57	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. 2021 ,		2
56	Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese Carriers.. 2022 , 2022, 9390539		
55	BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling.. <i>Scientific Reports</i> , 2022 , 12, 4445	4.9	0
54	Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future-Five-Years' Single-Institution Experience of 762 Consecutive Patients.. <i>Cancers</i> , 2022 , 14,	6.6	0
53	Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.. 2022 , 6, e2100140		1
52	The Impact of Mediterranean Dietary Intervention on Metabolic and Hormonal Parameters According to Variant Type.. <i>Frontiers in Genetics</i> , 2022 , 13, 820878	4.5	0
51	Helping Patients Understand and Cope with BRCA Mutations.. 2022 , 1		1
50	Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.. 2022 , 17, e0265387		2
49	BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.. 2022 , 10, 813457		1
48	Mutational Analysis of and Genes in Breast Cancer Patients from Eastern Sicily.. 2022 , 14, 1341-1352		
47	Anti-cancer peptide-based therapeutic strategies in solid tumors.. 2022 , 27, 33		2
46	Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.. 2022 ,		0
45	Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.. <i>BMC Cancer</i> , 2021 , 21, 1350	4.8	2
44	Differences in age at diagnosis of ovarian cancer for each mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy.. <i>Journal of Gynecologic Oncology</i> , 2022 ,	4	0
43	Unraveling the Genetic Architecture of Hepatoblastoma Risk: Birth Defects and Increased Burden of Germline Damaging Variants in Gastrointestinal/Renal Cancer Predisposition and DNA Repair Genes.. <i>Frontiers in Genetics</i> , 2022 , 13, 858396	4.5	0
42	Data_Sheet_1.docx. 2018 ,		
41	Presentation_1.PPTX. 2018 ,		

40 Table_1.DOCX. 2018,

39 Table_2.XLSX. 2018,

38 Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.. *Scientific Reports*, 2022, 12, 6704 4.9 0

37 Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.. *Journal of Medical Imaging and Radiation Oncology*, 2022, 1.7 1

36 Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma. *Frontiers in Molecular Biosciences*, 2021, 8, 619027 5.6 2

35 Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study.. *Journal of Medical Genetics*, 2022, 5.8 0

34 Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. *Cancers*, 2022, 14, 2405 6.6

33 Variable Number Tandem Repeats (VNTRs) as modifiers of breast cancer risk in carriers of BRCA1 185delAG.

32 Prevalence of Pathogenic Germline BRCA1/2 Variants and Their Association with Clinical Characteristics in Patients with Epithelial Ovarian Cancer in a Rural Area of Japan. *Genes*, 2022, 13, 1085 4.2

31 Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016. *BMC Women's Health*, 2022, 22, 2.9

30 Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers. *BMC Cancer*, 2022, 22, 4.8

29 Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer.

28 Identification of crucial hub genes and potential molecular mechanisms in breast cancer by integrated bioinformatics analysis and experimental validation. 2022, 106036 1

27 Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. 0

26 Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. 2022, 5, 0

25 Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy. 0

24 Hereditary ovarian cancer. 2022, 21, 123-134 0

23 A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. 0

- 22 Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant. **2022**, 103, 323 ○
- 21 Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma. **2022**, 18, 1743 ○
- 20 Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. **2022**, ○
- 19 Variable number tandem repeats (VNTRs) as modifiers of breast cancer risk in carriers of BRCA1 185delAG. ○
- 18 Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. **2022**, 10, 3008 ○
- 17 BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers. ○
- 16 The expression and mutation of BRCA1/2 genes in ovarian cancer: a global systematic study. 1-9 ○
- 15 Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer. **2023**, 15, 563 ○
- 14 Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine. 12, ○
- 13 Ovarian cancer onset across differentBRCAmutation types: a view to a more tailored approach forBRCAmutated patients. ijgc-2022-003893 2
- 12 Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes. **2023**, 173, 1-7 ○
- 11 Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor. ○
- 10 Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko-EVE). ○
- 9 Hereditary cancer syndromes. 14, 40-68 ○
- 8 Variant-specific Mendelian Risk Prediction Model. ○
- 7 Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer. ○
- 6 Pancreatic cancer cluster region identified inBRCA2. jmg-2022-109111 ○
- 5 Evaluation of the Association between FGFR2 Gene Polymorphisms and Breast Cancer Risk in the Bangladeshi Population. **2023**, 14, 819 ○

- 4 Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants. ○
- 3 Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. **2023**, 153, 40055 ○
- 2 The pathogenic role of the BRCA2 c. 7847C >T (p.Ser2616Phe) variant in breast and ovarian cancer predisposition. ○
- 1 Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays. **2023**, 23, ○